IsoPSA Test Better Than PSA Test at Detecting Prostate Cancer, Clinical Trial Shows

IsoPSA Test Better Than PSA Test at Detecting Prostate Cancer, Clinical Trial Shows
Cleveland Diagnostics' IsoPSA prostate cancer test is significantly better than a standard PSA test at identifying those with prostate cancer and those at risk of developing an aggressive form of the disease, according to the interim clinical trial results. The findings suggest that not only can IsoPSA do a better of identifying those who needed treatment, but also reduce unnecessary biopsies. The research, “The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report,” was published in the journal European Urology. Eric Klein, chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute, led the study, which included researchers from the Cleveland Clinic, Kaiser Permanente Northwest, the Michigan Institute of Urology, and other organizations. “PSA has been the mainstay test in screening and diagnosing of prostate cancer for over two decades, but its sensitivity to cancer is negated by its lack of specificity for the same, resulting in millions of unnecessary biopsies and billions of precious healthcare dollars wasted annually,” Dr. Arnon Chait, the CEO of Cleveland Diagnostics, said in a press release. PSA is short for a protein named prostate-specific antigen. A PSA test measures the protein's levels in a person's blood. High levels can mean cancer, but other conditions -- such as an enlarged or inflamed prostate -- can produce high levels as well. This means the PSA test generates a lot of false-positive cancer readings. Doctors often resort to biopsies to see whether high levels of PSA are actually designating cancer. But only
Subscribe or to access all post and page content.